Merck up after FDA approves combination treatment for muscle invasive bladder cancer

Astellas Pharma

21/11/2025 18:12

** Shares of drugmaker Merck MRK.N up 5.4% at $100.1

** U.S. FDA says it has approved Merck's combination therapy to treat muscle invasive bladder cancer

** Merck's Keytruda in combination with enfortumab vedotin-ejfv, developed by Astellas Pharma 4503.T and Seagen, now acquired by Pfizer PFE.N, is approved as a immunotherapy to reduce tumor size, kill cancer cells, and improve surgical outcomes

** Muscle-invasive bladder cancer is a more aggressive cancer that has grown into the muscle layer of the bladder wall that has high risk of spreading to other parts of the body and requires aggressive treatment

** Including session's move, stock up 0.25% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))